C-3GJZNeuroClues
eye-tracking, neurological biomarkers, AI
diagnostics
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-3GJZ
C-3GJZC-3GJZeye-tracking, neurological biomarkers, AI
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Venture and Growth Capital | Corporate Law | Osborne Clarke Skip to main content People Expertise Toggle submenu Sectors Technology, Media and Telecommunications Energy and Energy Transition Life Sciences and Healthcare The Built Environment Financial Services Infrastructure Mobility Retail and Consumer Services Banking and finance Commercial Competition, antitrust and trade Corporate Dispute resolution Employment and pensions ESG – Environmental, Social and Governance Infrastructure services Intellectual property IT and data Public law Real estate Regulatory and compliance Tax All Services Os … chnology company, on its £62m Series D funding round led by the National Wealth Fund and the Scottish National Investment Bank. Foresight We advised on a significant investment into geothermal energy company 85 Degrees Renewables. The investment will enable 85 Degrees to fund a 61.8 MW geothermal energy project in the Netherland's South Holland province. 13books Capital We advised on a £8.5m Series A investment into The Electric Car Scheme, a leading innovative EV salary sacr … chnology company, on its £62m Series D funding round led by the National Wealth Fund and the Scottish National Investment Bank. Foresight We advised on a significant investment into geothermal energy company 85 Degrees Renewables. The investment will enable 85 Degrees to fund a 61.8 MW geothermal energy project in the Netherland's South Holland province. 13books Capital We advised on a £8.5m Series A investment into The Electric Car Scheme, a leading innovative EV salary sacr … 6 Read time 5m Tax The new UK carried interest regime takes effect: what should fund managers be considering? The regime is now in force bringing carried interest within the scope of income tax 26/05/2026 Read time 3m Corporate EU Inc: Commission proposes single company structure for all 27 member states The ambition is undeniable, but will the final rules live up to it? 21/05/2026 Read time 6m Knowledge Notes The UK King's Speech – what can business expect this year? Th … edition, we focus on the upcoming 6 July employment-related securities returns deadline and some employee tax developments in... 13/05/2026 Read time 1m Dispute resolution English Commercial Court expands application of legal advice privilege to intra-client communications Glencore ruling settles question left open by Three Rivers on privilege f
neuroClues® | Eye Movement Biomarkers for Neurological Disorders Science Our research Product The neuroClues® eyetracker The paradigms The implementation Clinical Differential diagnosis Atypical Parkinson About us Team Career FAQ News More results Book a demo User portal Book a demo User Portal Science Our research Product The neuroClues® eyetracker The paradigms The implementation Clinical Differential diagnosis Atypical Parkinson About us Team Career FAQ News ce marked · class IIa MD Expand your neurological assesment. Evaluate brain function in clinical practice with objective, reproducible
Olivier Legrain - 2026 Portfolio - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks Corporates and Startups Corp Dev and … Co-Investors Apr 08, 2026 neuroClues Series A $11.6M Teampact Ventures , White Fund and 5 more Apr 30, 2024 neuroClues Series A $5.36M White Fund , Europa and 2 more Nov 08, 2021 neuroClues Seed $4.86M Invest.BW , Graph Ventures and 4 more View all Investments by Olivier Legrain View complete profile of Olivier Legrain FAQs about Olivier Legrain What companies are in Olivier Legrain's investment portfolio? Olivier Legrain's investment portfolio includes neuroClues
Delighted to announce the successful €10M Series A of neuroClues, a key milestone for a company that is truly redefining the future of neurology. The fundraising will contribute to bring AI powered… | Manolo Di Donato LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices … prevention. In this context, this Series A is led by Teampact.ventures , White Fund SA and the European Investment Bank (EIB) , with continued support from invest.bw , LeanSquare and Wallonie Entreprendre . 45 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in More Relevant Posts Sheba Medical Center, Tel Hashomer 34,306 followers 2mo Report this post Following the launch of ARC Landing Boston , we’re excited to spotlight the first cohort of startu … ment, the pipeline gets even bigger. The Life Sciences Innovative Manufacturing Fund from the Department for Science, Innovation and Technology is on track to unlock £1 billion by summer, supporting medicines for cancer, bipolar disorder, neurodegenerative conditions and more — as well as over 500 jobs across the UK. The North West is at the centre of it, with Liverpool and Manchester chosen to pilot the new Life Sciences Large Investment Portfolio. The UK life science moment … is happen. Newfund announces the final close of HEKA at €60M, the only European fund entirely dedicated to BrainTech. A new market is emerging at the convergence of AI, advanced imaging, digital therapeutics and biotech applied to the brain. It's growing fast, dominated 85% by the US. Yet Europe holds a major scientific edge in neuroscience. The missing piece wasn't the science. It was the capital, and the specialization to deploy it well. That's what HEKA was built for. Sinc
About us Science Our research Product The neuroClues® eyetracker The paradigms The implementation Clinical Differential diagnosis Atypical Parkinson About us Team Career FAQ News More results Book a demo User Portal Book a demo User Portal Science Our research Product The neuroClues® eyetracker The paradigms The implementation Clinical Differential diagnosis Atypical Parkinson About us Team Career FAQ News Where purpose meets passion. As a team of researchers, doctors and engineers, we are driven by our singular mission: expand neurologic care. " data-embed-response-width="426" data-embed-resp … and US markets. Nov 2021 Dec 2022 ISO 13485:2016 certification & EIC grant In June 2022, the company obtained the ISO 13485:2016 certification for design and development of eyetracking devices. In December 2022, P3Lab was awarded blended funding, of which a €2.5 million grant, and up to €9 million in equity by the European Commission under the highly selective EIC Accelerator program. Dec 2022 Mar 2023 ICEBERG Cohort The company concluded a research agreement
New Funding Rounds in eye-tracking | VentureRadar 0){if($('#i_b_toggleMore').hasClass('active')){Search_Elastic();}else{Search_DeconstructSearchString();Search_Elastic(false);event.preventDefault();}}else{event.preventDefault();}}" onclick="this.removeAttribute('readonly');" ontouchstart="this.removeAttribute('readonly');" id="i_t_Search" name="VRSearch" readonly> All Ranked Organisation Names Apps and Links Homepage (myVR) Funding Deals Hub Similar Companies App Articles Manage Account Logout Login Free Sign-up Forgotten your password? By continuing, you agree to VentureRadar's Terms o … om Create a Free Account to access Downloads View More With A Free Account Submit or Claim Your Company Register for Free How to Increase your Company's exposure OR Create an Account for More Register for Free View Pricing for full Business Subscription OR More about VentureRadar VentureRadar Database VentureRadar Services VentureRadar for Companies Terms & Conditions Privacy Policy Cookie Policy Copyright ©2024 VentureRadar. All Rights Reserved. Upgr … nditions Privacy Policy Cookie Policy Contact Us Twitter LinkedIn | Submit a Company Directory of Companies Login Free Sign-up for VentureRadar access or By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie Policy . Free Sign-up for VentureRadar access You must have cookies enabled to create an account with VentureRadar Refresh (When Cookies Enabled) Return to home page Create a Free Account to Follow Companies To continue, pleas
EIC Fund | Portfolio, Investments & AUM | Caplight NEW Caplight raises a $16M Series A, led by BlackRock and Fin Capital → Products Solutions Resources Log in Book a demo Investors EIC Fund EIC Fund — eic.ec.europa.eu Overview The EIC Fund is the venture capital arm of the European Innovation Council (EIC), established by the European Commission to make direct equity and quasi-equity investments in European high-impact and deep-tech start-ups and scale-ups. It provides patient capital to bridge the financing gap for breakthrough innovations, often in combination with grants from the EIC Ac … 2026 Seed Co-investor neuroClues Apr 2026 Series A Lead Arkadia Space Mar 2026 Grant Co-investor View all investments Sector & Stage Mix Industry, funding stage, and valuation band breakdowns. Premium Seed Series A Series B Growth Unlock portfolio analytics Sign up to view full sector, stage, and valuation breakdowns for this investor. Unlock full analytics Investment Activity Yearly cadence, pace, and funding raised over time. Premium 2021 2022 2023 2024 2025 2026 Unloc … ent trends and funding raised over time. Unlock full analytics FAQ Where is EIC Fund based? When was EIC Fund founded? How many portfolio companies does EIC Fund have? What are some companies in EIC Fund's portfolio? What was EIC Fund's most recent investment? What sectors does EIC Fund focus on? What company stages does EIC Fund focus on? What is EIC Fund's AUM? Firmographic Details Headquarters — Year Founded N/A Institutional Data Access Join leading institu
Belgian Pharma Updates: April 2026 LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy … s from a short eye‑movement exam. The round was led by Teampact Ventures, White Fund, and the EIC Fund, bringing total capital raised (including non‑dilutive funding) to €25 million and supporting rapid commercial expansion and large‑scale clinical data generation. Find more information here: https://neuroclues.com/neuroclues-raises-a-series-a-to-bring-ai-powered-neurological-biomarkers-to-every-clinician-in-europe-and-prepares-u-s-entry/ 🧪 Telix Pharmaceuticals Limited anno … armaceuticals announced that the U.S. FDA has accepted the resubmitted New Drug Application (NDA) for TLX101‑Px (Pixclara®), an investigational PET imaging agent for glioma, including recurrent or progressive brain cancer in both adult and pediatric patients. The FDA assigned a PDUFA target action date of 11 September 2026, marking a significant regulatory milestone. Pixclara has already received Fast Track and Orphan Drug designations, reflecting its potential to address a m … rope. Telix Pharmaceuticals announced that the European Marketing Authorisation Application (MAA) for TLX101‑Px (Pixlumi®), a PET imaging agent for glioma, has been validated and accepted for review. The application has entered the standard 210‑day assessment phase, marking a key regulatory milestone toward European approval. Pixlumi® is designed to improve the ability to distinguish tumor progression or recurrence from treatment‑related changes in both adult and pediatric pa … , has deprioritized other indications, and is raising a €70 million Series B to fund clinical development, manufacturing, and regulatory activities. Find more information here: https://bioxodes.com/newsroom/press-releases/bioxodes-expands-clinical-advisory-board-shares-pivotal-trial-design-for-biox-101-in-intracerebral-hemorrhage 🧠 UCB announces
Neurological diagnosis, apparatus and instruments Skip to main content --> Main navigation Close Back --> --> --> Home Help & Arrival Contact International Representatives Arrival Hotel & CityInfos FAQ Exhibit Trade Fair Participation Online registration Become an exhibitor Stand Cost Calculator Focus topics Trade fair preparations MEDICA HOSPITAL OF THE FUTURE Information Contact persons Download center At a glance Service ABC Hotel & CityInfos Stand constructor portal Traffic regulations Services Fair Match Online-Order-System (OOS) Exhibitor Profile Exhibitor dashboard Scan2Lead Logos & ban … Press Accreditation Press contact Press releases Exhibit Exhibit Exhibit Online Application Online Order System Marketing Services Exhibitor contact Dashboard Parallel event Parallel event Parallel event COMPAMED About MEDICA About MEDICA About MEDICA Product Categories At a glance Newsletter Spheres of MEDICA-Magazine Contact & Support Write to us Hotline +49 211 / 4560-01 FAQs Digital Services Act (DSA) Legal Imprint Privacy Policy Accessibility Compliance Cookie Settings F
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
InnoStars - 🚀 Big News for Fetalix, an EIT... Facebook Log In InnoStars's Post InnoStars February 12, 2025 · Shared with Public Big News for Fetalix, an EIT Health -supported start-up from Portugal! They just received the SIFIDE certification from the Portuguese Agência Nacional de Inovação - a major milestone recognising their commitment to cutting-edge research and development! Why is this important? This certification: Confirms their ability to drive groundbreaking R&D Makes them eligible for valuable tax incentives, enabling further innovation and scaling Increases their attracti
Acknowledgements Skip to Content Disclaimer Disclaimer MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content. Facebook Twitter LinkedIn YouTube Instagram International Congress of Parkinson’s Disease and Movement Disorders ® Menu Attend Registration Housing & Travel Program Scientific Program Schedule & Events Certificates A
EISMEA - Items skip to main content en Select language Close bg български cs čeština da dansk de Deutsch el Ελληνικά en English es español et eesti fi suomi fr français ga Gaeilge hr hrvatski hu magyar is íslenska it italiano lt lietuvių lv latviešu mt Malti nl Nederlands no norsk pl polski pt português ro română sk slovenčina sl slovenščina sv svenska Search Search Search Search Newsroom Menu Close Menu Back Previous items Next items European Commission > EISMEA Topics Events - test 16012024 Horizon 2020 Archives Overview News Content Types ::: ecl-inpage-navigation__item--active -- … ews Content Types ::: ecl-inpage-navigation__item--active --> Content Types ALL Award Event Funding Interview News Press release Project Publication Speech Surveys and consultations Tenders Vacancies News Rss Feed for News First project completes full EIC journey The iSMILE project (company Qubedot) has become the first-ever EIC funded project to complete the full EIC journey. Previously securing both EIC Pathfinder and EIC Transition funding, and now moving via the ‘Fast Tra … via the ‘Fast Track’ to EIC Accelerator, where it has been selected to receive grant and equity support through the EIC Fund. Meet the first-ever project to secure all three EIC funding opportunities The iSMILE project – integrated scalable microLED engines – has become the first-ever EIC funded project that has managed to secure both EIC Pathfinder and EIC Transition funding in the past and has been selected for the EIC Accelerator funding in a highly competitive pro … nbsp; EIC ePitching on MedTech The EIC is providing another opportunity for EIC Fund-selected beneficiaries to showcase their MedTech solutions to a panel of top European Venture Capitalists on 18 June 2024. Join the European Pavilion at GITEX GLOBAL 2024 EIC companies are warmly invited to showcase their innovations at the European Pavilion at GITEX GLOBAL in Dubai, supported by the EIC International Trade Fairs and USA Soft-landing Programme 3.0. Simultaneous … ites EIC Pathfinder, EIC Transition, FET Flagship, and ERC-POC beneficiaries to apply for the EIC T2M Innovation Discovery Training. EIC T2M Venture Building’s Tech Demo Day on Engineering The EIC Tech to Market Venture Building Programme enrolled 5 more Pathfinder and Transition projects in the first phase of its process, the Tech Demo Da
NeuroClues by P3Lab, une start-up néo-louvaniste, gagnante de l'EIC Accelerator, grâce à son casque portable! - NCP Aller au contenu Envelope A propos Équipe Actualités Agenda A propos Équipe Actualités Agenda Rechercher Newsletter Faq Contact Newsletter Faq Contact FR EN Informer Accompagner Connecter Les programmes européens Thématiques & appels ouverts Succès & témoignages Informer Accompagner Connecter Les programmes européens Thématiques & appels ouverts Succès & témoignages « Avant on envisageait le futur jusqu’à 6 mois, ce financement nous permet de savoir … nous a énormément aidés dans la relecture de ce dossier afin d’obtenir ce grant », nous explique Antoine Pouppez. L’accompagnement offert par la conseillère du NCP Wallonie Valentina Albarani a joué un rôle clé dans l’obtention de ce graal. Et le CEO de NeuroClues by P3Lab de préciser: « Si j’avais un conseil à donner aux candidats qui souhaitent obtenir un EIC Accelerator, je leur conseillerais de contacter leur NCP pour bien comprendre la philosophie … leur conseillerais de contacter leur NCP pour bien comprendre la philosophie du grant, parce que ce n’est pas applicable à tout le monde. Il faut donc s’assurer de plusieurs choses: d’être qualifié de « deep tech », d’avoir une « vallée de la mort », parce que cela prend du temps et ce serait dommage de consacrer du temps à un projet qui ne serait pas aligné à la philosophie du financement. » Antoine Pouppez a un deuxième conseil aux entrepreneurs qui
neuroClues - French Corner at JP Morgan Week Close Search Search for: Search Skip to content French Corner at JP Morgan Week Everything you need to know about the French Healthcare Days at J.P Morgan, by Business France Menu Home Delegation Biotech & Pharma TechBio Medtech Digital Health Services Program French Corner Agenda Side Events Partners Contact us More Search for: Search Open Search neuroClues 1 décembre 2025 4 décembre 2025 by bsaintleger in Digital Health neuroClues Key information: – Digital Health – Therapeutic areas: Neurology, Movement disorders, Ophthalmology, C
neuroClues® | Eye Movement Biomarkers for Neurological Disorders Science Our research Product The neuroClues® eyetracker The paradigms The implementation Clinical Differential diagnosis Atypical Parkinson About us Team Career FAQ News More results Book a demo User portal Book a demo User Portal Science Our research Product The neuroClues® eyetracker The paradigms The implementation Clinical Differential diagnosis Atypical Parkinson About us Team Career FAQ News ce marked · class IIa MD Expand your neurological assesment. Evaluate brain function in clinical practice with objective, reproducible
With Pierre Pouget, as two of the founders of neuroClues (missed you Antoine Pouppez), we had the pleasure to attend the Indo-French forum: AI in Brain Health and Global Healthcare at AIIMS (All… | Pierre Daye LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any t
neuroClues has raised €10M to support Parkinson’s diagnosis Skip to content Toggle Navigation News Events TNW Conference June 19 & 20, 2025 All events Newsletters Partner with us Jobs Contact News Latest Deep tech Sustainability Ecosystems Data and security Fintech and ecommerce Future of work Conference media hub More Startups and technology Investors and funding Government and policy Corporates and innovation Podcast This article was published on April 7, 2026 Startups and technology neuroClues closes €10M Series A to bring its eye-tracking Parkinson’s diagnostic to European and US neuro … ty committed, and €5 million in a pre-Series A round in April 2024 led by White Fund and the EIC Accelerator, with participation from Invest.BW and business angels including Fiona du Monceau and Olivier Legrain, CEO of IBA. The new capital will be used to build out the commercial team, pursue FDA clearance in the United States in 2026, and expand into European markets. The company’s headquarters and manufacturing facility are in Louvain-la-Neuve, Belgium, with an office at th
Skip to content How It Works Pricing Blog Events Partners Search orgs, people, news, resources... ⌘K Sign In Get Started → Search organizations, people, news, resources, and content... / How It Works Pricing Blog Events Partners Sign In Get Started → Loading organizations... The OS for early-stage founders from day zero to raise. Subscribe Product How It Works Pricing Partners Resources Blog Events Contact Company About Privacy Terms © 2026 Startup Intros, Inc. San Francisco, CA · Made for Founders neuroClues: Funding, Team & Investors | Startup Intros Home / Organizations / neuroClues § P … ght among researchers, doctors, and engineers. They recognized the potential to apply established eye-tracking science to clinical settings, driven by a mission to enhance neurological care. Their combined expertise underpins the company's approach to advanced diagnostic capabilities. NeuroClues targets clinicians, empowering them with early diagnostic biomarkers for conditions like Parkinson's Disease, Alzheimer's Disease, and Multiple Sclerosis, often before visible symptom … ng US regulatory approvals, with strong growth via €4.7M seed (2021), €2.5M EIC grant plus up to €9M equity (2022), and €5M pre-Series A (2024) to enable commercial rollout.[1][2] Origin Story Founded in 2020 as P3Lab (rebranded to neuroClues), the company emerged from over 35 years of combined research by a team of researchers, doctors, and engineers focused on eye movement studies through modeling and experimental projects.[1][2] Frustrated by limitations in existing eye-tr
neuroClues raises €10 million Series A to become the brain’s stethoscope for early diagnosis of neurological disorders – BeBeez International No Result View All Result Private Data Membership options Login COUNTRY ITALY IBERIA FRANCE UK&IRELAND BENELUX DACH SCANDINAVIA&BALTICS PRIVATE EQUITY VENTURE CAPITAL PRIVATE DEBT DISTRESSED ASSETS REAL ESTATE FINTECH GREEN PREMIUM ItaHub HOT ItaHub Legal ItaHub Tax ItaHub Trend REPORT INSIGHT VIEW Private Data Subscribe COUNTRY ITALY IBERIA FRANCE UK&IRELAND BENELUX DACH SCANDINAVIA&BALTICS PRIVATE EQUITY VENTURE CAPITAL PRIVATE DE … the company to €25 million. The round is led by Teampact Ventures, White Fund and the EIC Fund (European Innovation Council), with participation from existing investors (InvestBW, Leansquare, Wallonie Entreprendre) and the support of Olivier Legrain, Chairman of the Board and CEO of IBA. “This Series A validates our technology and our ability to execute. CE certification in five months. First commercial deployments within weeks. A normative database project with
Osborne Clarke advises neuroClues® on €10 million Series A fundraising to bring AI powered neurological biomarkers across Europe and prepare U.S. entry | Osborne Clarke Skip to main content People Expertise Toggle submenu Sectors Technology, Media and Telecommunications Energy and Energy Transition Life Sciences and Healthcare The Built Environment Financial Services Infrastructure Mobility Retail and Consumer Services Banking and finance Commercial Competition, antitrust and trade Corporate Dispute resolution Employment and pensions ESG – Environmental, Social and Governance Infrastructure se … gical biomarkers from eye movements. The round, led by Teampact Ventures, White Fund and the EIC Fund (European Innovation Council), with participation from existing shareholders InvestBW, Leansquare and Wallonie Entreprendre, and the support of Olivier Legrain, Chairman of the Board and CEO of IBA, brings the total capital raised by neuroClues to EUR 25 million, including additional non-dilutive funding secured concurrently. Founded in 2020 by Antoine Pouppez, Pierre Daye an
neuroClues Asset Profile | Preqin Skip to main content Products Our products Preqin Pro Alternative assets data platform Private Markets Research Industry research Term Intelligence Benchmark LPA terms Preqin Benchmarks Industry's leading performance data Preqin Sustainability ESG data and insights Company Intelligence Companies & deals data Enterprise Data Solutions Flexible data delivery solutions Transaction Intelligence A $5.4tn transaction repository Client stories What our clients say Quick Links Our data Asset classes we cover Create a free account Newsletter Contribute data Co … r analysis Keep up with market trends Spot new business opportunities Benchmark fund terms Navigate private credit investing Quick Links Our data Asset classes we cover Create a free account Newsletter Contribute data Contact us Insights+ Private markets research Homepage Browse reports Search Search the research library Webinar recordings Join conversations with our analysts Meet the analysts Meet the team behind the reports Learn more Learn more about Private Markets Resear … r analysis Keep up with market trends Spot new business opportunities Benchmark fund terms Navigate private credit investing Insights+ Homepage Search Webinar recordings Meet the analysts Learn more News & content Homepage Events Free Benchmarks Data coverage map Preqin Profiles Preqin Academy Compensation calculator About Who we are Our corporate responsibility Partners Press hub Careers Contact us QuickLinks Our data Asset classes we cover Create a free account Newslett … ed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers. Request demo neuroClues - overview Established 2020 Location Louvain-la-Neuve, -, Belgium Primary Industry Medical Devices & Equipment About Founded in 2020 by co-founders Pierre Daye, Pierre Pouget, and Antoine Pouppez and based in Louvain-la-Neuve, Belgium, P3Lab SRL, trading under the name NeuroClues, is a devel … funding co-led by new investor Teampact Ventures with returning investors White Fund and European Innovation Council, with participation from other returning investors LeanSquare, Invest. BW and Wallonie Entreprendre. Individual investors also participated in the round. NeuroClues is a portable eye-tracking device specifically designed for the cl
neuroClues by P3Lab - BioWin BioWin BioWin About us Mission & Vision Values & History Ecosystem Strategic areas Team Governing Board Our network Directory of BioWin members BioWin Partners Join our innovative network Success stories Services Innovate Our innovation offer Funding opportunities Submit a project R&D Project directory Connect International development Talent Communicate Boost your visibility Events Calendar Become a sponsor of our events News Resources Media kit Resources Library Search Join us Marketplace Job board Contact Biowin members neuroClues by P3Lab Rue du Mor … ont 33 1341 CEROUX-MOUSTY Belgium [email protected] p3lab.com Type Company Application domains Health-tech Core business Production R&D Technology AI Digital health Medical devices Personalised medicine Therapeutic area Neurology Ophtalmology neuroClues develops an eye-tracking solution for early detection of neurological diseases by analyzing eye movements to identify specific biomarkers About In a world where neurological disorders will affect 1 person in 3 and whe
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
EISMEA - CES 2025: neuroClues, the start-up developing a “brain stethoscope” skip to main content en Select language Close bg български cs čeština da dansk de Deutsch el Ελληνικά en English es español et eesti fi suomi fr français ga Gaeilge hr hrvatski hu magyar is íslenska it italiano lt lietuvių lv latviešu mt Malti nl Nederlands no norsk pl polski pt português ro română sk slovenčina sl slovenščina sv svenska Search Search Search Search Newsroom Menu Close Menu Back Previous items Next items European Commission > EISMEA Topics Events - test 16012024 Horizon 2020 Archives Overview … re than €12 million, including €5 million in 2024, from investors such as White Fund, Graph Ventures, Invest. BW, LeanSquare and WING, as well as from institutions such as the Walloon region in Belgium. It has also received €2.5 million in grants from the European Innovation Council (EIC) accelerator. Date : 07/01/2025 Specializing in the diagnosis of neurodegenerative diseases, the Franco-Belgian start-up has just obtained the CE mark. This sesame allows it to launch t
OneMedNet Announces Strategic Neuro Data Partnership with Risorius to Advance EEG-Based Digital Biomarkers | FirstWord HEALTHTECH You need to enable JavaScript to run this app. Loading...
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
%PDF-1.3 %���� 1360 0 obj > endobj xref 1360 33 0000000016 00000 n 0000002516 00000 n 0000002836 00000 n 0000002969 00000 n 0000003866 00000 n 0000004218 00000 n 0000004567 00000 n 0000004682 00000 n 0000004939 00000 n 0000008666 00000 n 0000012267 00000 n 0000014991 00000 n 0000016943 00000 n 0000019023 00000 n 0000021158 00000 n 0000021484 00000 n 0000022247 00000 n 0000022506 00000 n 0000024478 00000 n 0000026777 00000 n 0000056620 00000 n 0000083807 00000 n 0000084936 00000 n 0000085247 00000 n 0000085597 00000 n 0000087196 00000 n 0000087535 00000 n 0000087905 00000 n 0000088334 00000 n 0 … �K�����λP��;��i���m����)�!}�f�y y��_�&� endstream endobj 1389 0 obj >stream application/pdf Nanos logo white 2017-03-15T07:42:04-10:00 2017-03-15T07:42:04-10:00 2017-03-15T07:42:04-10:00 Adobe Illustrator CC 2017 (Macintosh) uuid:baffb610-eba3-3a41-b301-0d47d0f3c899 xmp.did:d378d4d5-2d2f-4c63-bbbf-2359253338ff uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:d1c078a0-2746-42b2-b0d1-25aedff8fb1e xmp.did:1b6690ed-28a8-c141-9479-b6a9cf6be651 uuid:5D20892493BFDB11914A8590 … ��0�8�=I���6 ���@�`�#�5��^[Qᠰ�ו�Խ؏� �y�+dL�I�� ���������>*g��# �,�]:�frϲRfP��^�Tt&`��Q�Y��*ô=��Q��D{O��4 ��N��/ơv'G������Q�9#ʁU�xI�Hl���Ә�*x��`S����!�� ��ט �'5ɿ�w Q1��a ��Y ��7��6���a�;��6��qsH���D�.& ����8�"��D�h�X �%�D79ZK�������t��+A�̣*a~2FB%��x��{�מ��&�G+l ���+� h�G��60`�*)Gkf���!�|�-�x�;O��� V�k� �676E� � �nK�e �b G� �� Qk[f|�.�P�R-� I�|~HF���pi6�_�Ap�gk��J�%��,�H�%/����t���y�jT�9��k�A� ,���dx�-�T��?/� F`co1�E��b�F��/ … B495697D613E6ECB339F adobe:docid:photoshop:8c275657-0c6c-9d43-a578-9db54d98327f application/pdf uuid:578afae5-1e1a-4703-a0f9-f269bc2f44d4 adobe:docid:photoshop:72cd4279-c6c4-e149-828a-d20ec1f605c7 xmp.did:dac0d981-30cc-5a41-8d39-31b8b1c84828 created xmp.iid:dac0d981-30cc-5a41-8d39-31b8b1c84828 2022-01-31T15:56:20-07:00 Adobe Photoshop 21.2 (Windows) saved xmp.iid:89dbd062-8a55-ff49-9a48-491c66835cc7 2022-01-31T15:58:48-07:00 Adobe Photoshop 21.2 (Windows) / saved xmp.iid:d4d3 … 489d8 2024-01-09T12:02:43-07:00 Adobe Photoshop 25.1 (Windows) / converted from application/vnd.adobe.photoshop to application/pdf derived converted from application/vnd.adobe.photoshop to application/pdf saved xmp.iid:002f80ad-b852-b743-8be0-d296e01fcea8 2024-01-09T12:02:43-07:00 Adobe Photoshop 25.1 (Windows) / xmp.iid:d4d35312-af87-9d4d-950d-7
Keen to see neuroClues at Ghent Slush'D ? I'll be happy to give you a tour on how we plan become the brain stethoscope 🧠🩺 Thanks to Wallonia Export & Investment Agency and invest.bw for… | Antoine Pouppez LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices
#medtech #ai #mdr #medtech #innovation #neurology #healthcare #europeaninnovation #startup | Antoine Pouppez | 72 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join … m, board members ( Olivier Legrain & Diane Lejeune ), and investors ( White Fund SA , Graph Ventures , invest.bw , LeanSquare & Wallonie Entreprendre ) for their continued support. 🙏 Special thanks also to the Walloon Region (DGO6) and the European Commission Fund (EIC) for believing in our vision. ✨ The future of neurological care is being built in Europe, and neuroClues is proud to be leading the way. Stay tuned for more updates as we begin our commercial rollout a
#cap48 #neurodiversity #inclusion #medtech #neuroclues | Antoine Pouppez | 26 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s … oin now Sign in Antoine Pouppez 3w Report this post Yesterday, we won the CAP48 Prize 2026 : "Employment" category. 🏆 But here's what that actually means ? Two of our collaborators who built our technology see the world differently. They bring a level of focus, precision, and pattern recognition that shapes our product every single day. 🧩 We didn't hire them despite that. We hired them because of it. They contribute directly to our value proposition, neuroClues wouldn't exi
neuroClues SRL of Louvain-la-Neuve at MEDICA 2025 in Düsseldorf Skip to main content Main navigation Close Back --> --> --> Home Help & Arrival Contact International Representatives Arrival Hotel & CityInfos FAQ Exhibit Trade Fair Participation Online registration Become an exhibitor Stand Cost Calculator Trade fair preparations Information Contact persons Download center At a glance Service ABC Hotel & CityInfos Stand constructor portal Traffic regulations Services Fair Match Online-Order-System (OOS) Exhibitor Profile Exhibitor dashboard Scan2Lead Logos & banners Trade fair presence Stand co … Press Accreditation Press contact Press releases Exhibit Exhibit Exhibit Online Application Online Order System Marketing Services Exhibitor contact Dashboard Parallel event Parallel event Parallel event MEDICA About COMPAMED About COMPAMED About COMPAMED Product Categories At a glance Newsletter Spheres of COMPAMED-Magazine Contact & Support Write to us Hotline +49 211 /4560-01 FAQs Digital Services Act (DSA) Legal Imprint Privacy Policy Accessibility Compliance Cookie Setti
Spotlight Pathology Raises £1.4m in Seed Funding for AI Cancer Diagnosis Tools | UK Innovation & Science Seed Fund [UKI2S] posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join Li … in Seed Funding for AI Cancer Diagnosis Tools UK Innovation & Science Seed Fund [UKI2S] 10,323 followers 3mo Report this post 💡 Spotlight Pathology , a UK healthtech company developing AI tools to support faster and more consistent diagnosis of blood cancers, has raised £1.4m in seed funding to support the next phase of product development, regulatory progress and clinical adoption. The funding round is co-led by the UK Innovation & Science Seed Fund [UKI2S] (Manage … Fund [UKI2S] (Managed by Future Planet Capital ) and Liverpool City Region Seed Fund (LCR Seed Fund) , managed by AXM VENTURE CAPITAL LIMITED , with participation from River Capital , alongside follow-on investment from existing backers Deepbridge Capital , EHE Venture Studio and LYVA Labs . Based at UK Research and Innovation ’s Daresbury Laboratory campus, Spotlight Pathology ’s AI software helps pathologists prioritise cases and reach decisions sooner - supporting earlier … h system. The funding demonstrates the role of UK Innovation & Science Seed Fund [UKI2S] ’s seed portfolio in backing companies emerging from the UK’s public research and innovation base. 🗞️ Read more here: https://lnkd.in/e7Nu3H57 Sakura Holloway , Samantha Perona (Westgate) , Neil Vose , Martin Fergie , Riccardo F. , Dr Connor James R. , Chris Hemmall (Ball) Future Planet Capital | Future Planet Capital Regional #portfoliocompany #announcement #ai #tech #science #ventu … ral of their clinical cohorts This Series A is led by Teampact.ventures , White Fund SA and the EIC Fund ( European Investment Bank (EIB) ), with continued support from invest.bw , LeanSquare and Wallonie Entreprendre 🎯 Our ambition remains unchanged: to make neurological assessment fast, objective and accessible for every clinician and to shift
NeuroClues accélère la détection des maladies neurologiques - ON HEALTH --> --> --> --> --> --> --> Accueil Actualités Agenda santé Qui sommes-nous ? Nous contacter Nos Partenaires Newsletter Recherche NeuroClues accélère la détection des maladies neurologiques 23 avril 2026 | In Articles | By Antonin Tabard La medtech européenne NeuroClues franchit une nouvelle étape dans la détection précoce des maladies neurologiques. La start-up franco-belge vient d’annoncer une levée de fonds de dix millions d’euros en série A pour déployer à grande échelle sa technologie basée sur l’analyse des mou
Kourosh Sam Kamali's Cambridge NeuroWorks Breakthroughs | Advanced Research + Invention Agency (ARIA) posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Co … euroWorks Frontier Fellow Kourosh Sam Kamali , CEO of Myonerv , to hear how our fellowship programme has helped accelerate the development of a wearable neurostimulator for stroke rehabilitation. Inspired by his 10-year-old cousin’s experience with a stroke, Sam and his team are building a technology designed to support recovery through personalised neurostimulation and remote physiotherapy. Over the past year, Myonerv has raised over £215k, built multiple prototypes and is p … , with participation from business angels and the Danish Export and Investment Fund 🚀 MedicQuant is developing a point-of-care test that can measure the level of blood-thinning medication directly at the patient’s bedside, potentially eliminating critical waiting times in treatment. As CEO and co-founder Line Debois Frejlev Nielsen says: “The first time a stroke patient gets faster treatment because our device helped doctors get an answer earlier, it will mean everything. T … neuroClues has raised €10M in Series A funding led by Teampact.ventures , White Fund SA, and the European Innovation Council Fund to scale an AI-powered eye-tracking platform for objective neurological biomarkers across Europe. What matters here is where the AI sits in care delivery. neuroClues is not positioning itself as another retrospective analytics layer. Its CE-marked Class IIa device captures high-speed infrared eye-movement data during a normal neurology visit, then … ed: €25M ● HQ: Louvain-la-Neuve, Belgium ● Investors: Teampact.ventures ; White Fund SA ; European Innovation Council Fund; invest.bw ; LeanSquare ; Wallonie Entreprendre ● Partners: Institut du Cerveau – Paris Brain Institute (2026) 77 5 Comments Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in LifeSciences@Work 2,64
EU-Startups - neuroClues, a French-Belgian MedTech... Facebook Log In EU-Startups's Post EU-Startups April 7 · Shared with Public neuroClues, a French-Belgian MedTech startup, has raised a €10 million Series A, along with additional non-dilutive funding, bringing the total capital raised by the company to €25 million. The round is led by Teampact.ventures, White Fund and the EIC Fund (European Innovation Council), with participation from existing investors ( invest.bw , LeanSquare, Wallonie Entreprendre) and the support of Olivier Legrain, Chairman of the Board and CEO of IBA. “This Serie
Bernard Banga | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market China CAR T Alzhei … a minimally invasive version of Defymed's Mailpan device, which will extend the application range for this artificial pancreas to include other chronic pathologies besides type 1 diabetes. Read More Mauna Kea begins marketing its new generation of real-time in vivo cell imaging technology in US and Europe Oct. 28, 2021 By Bernard Banga PARIS – Mauna Kea Technologies SA reported the commercial launch of a new generation of its in vivo cellular imaging for diagnostics in gastro
NANOS 2026 Exhibitor/Sponsor Kit | North American Neuro-Ophthalmology Society Your NANOS 2026 Exhibitor Guide NANOS is pleased to welcome a strong and growing group of exhibitors to the 2026 Annual Meeting. This page provides all essential information for your participation, including table assignments, required forms, shipping and logistics details, exhibit hours, registration options, and on-site support contacts. Please review the materials carefully to ensure a smooth and successful experience at this year's meeting. Exhibitor List NANOS is pleased to welcome the following organi … Exhibitor Forms All exhibitors must complete the following items by the stated deadline to ensure full participation at NANOS 2026: Exhibitor Rules and Regulations Consent Form Exhibitor Information Survey These forms provide NANOS with essential details for planning, logistics, and on-site support. Exhibitors who do not complete the required forms by the deadline may experience delays in setup or access to exhibit materials. Please contact [email protected] for any … 2026: 6:00 am - 9:00 am All materials must be fully set up by the posted deadline. Setup is not permitted during designated blackout periods due to scheduled events in the exhibit space. Exhibit Hours Saturday, March 21, 2026: 10:00 am - 6:00 pm Sunday, March 22, 2026: 9:00 am - 6:00 pm Monday, March 23, 2026: 9:30 am - 7:00 pm Breakdown/Load-Out Monday, March 23, 2026: 7:30 pm - midnight All exhibit materials must be removed by the posted deadline. Exhibito … . A cleaning fee may be assessed for any exhibit space not fully cleared by the deadline. Signage & Printing Exhibitors may display table signs, pop-up banners, and freestanding signage that fits entirely within their assigned 8' x 8' exhibit space. Signage may not be affixed to hotel walls, tables, or other surfaces. Exhibitors may use any printing vendor of their choice. For on-site support, the following vendor will be available throughout the meeting: FedEx … AM NANOS Resources Dr. Thomas Carlow Thomas and Susan Carlow Young Investigator Award Fund NANOS International Community Meetings NANOS 2027 San Diego On-Demand 2026 On-Demand 2026 Log In Past Meetings Other Meetings of Interest Careers in NO For Students Practice Opportunities Becoming a Neuro-Ophthalmologist Post a Job YONO Portal Patients Find
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Industry Partner - ean.org Toggle Navigationn EAN EAN back Home Home back About Us Members Organisation Partners and Collaborators Media & Press Research Research back Resources EAN Guidelines Programmes and Funding EANcore COVID-19 Projects Learn Learn back eLearning Career development Educational Events Fellowships and Funding Meet Meet back Congresses Awardees Gallery Videos Join Join back Apply Renew About Advocacy Advocacy back Key Projects & Activities Statements & Publications Congress 2026 Congress 2026 back About About back About Register Register back Register Programme P
Neurotech Notables #52: April 1-15, 2026 - by Naveen Rao Subscribe Sign in Neurotech Notables #52: April 1-15, 2026 Hackers, Helpers, Founders, Friends Naveen Rao Apr 16, 2026 12 2 1 Share ☀️Hello Again Readers Neurotech news has been springing up all month, with commercial activity accelerating around the world. Here’s what I tracked over the last two weeks. Fresh fundraising news by Beacon, Neuroclues, Egra, Indivi.io, and Connectome Health, as well as new fund announcements from Heka and Ground Effect. The braintrust behind neural dust launched Epia Neuro a BCI platform for Stroke. Precisio … M ( Linkedin ) neuroClues secures €10M Series A led by Teampact.ventures, White Fund SA and the EIC Fund ( LinkedIn ) EGRA raises a $5.5M Pre-Seed Round ( Linkedin ) Connectome Health raises 2 million USD pre-seed round ( Linkedin ) Leclercq American Capital LLC invests in Indivi.io, a Swiss specialist in digital biomarkers for neurology ( Eurozone ) M2D2 $200K Challenge Names 2026 Pitch Contest Winners ( UML Press Release ) B.C. not-for-profits launch venture funds to turn r … o turn research into revenue ( BIV ) Newfund raises €60m for Heka, a 60 million fund dedicated to braintech ( Sifted ) Ground Effect Ventures launches new fund focused on neurotech and “the convergence of physical systems, biological signals, and applied intelligence” ( Linkedin ) Commercial Epia Neuro Launches to Develop Intent-Driven Neural Technology to Restore Function After Stroke and Address Cognitive Decline ( Business Wire | Wired ) Stay tuned for more insights from m … trategist ) American Brain Coalition Statement on the President’s FY2027 Budget Proposal ( ABC ) Request for Information on Draft NIH Resources to Support Implantable Device Trials ( NIH ) Draft resources here . Deadline May 25 2026 Shuren and Former FDA Colleagues Launch New Firm ( Market Pathways ) 📌Community Board 🆕 Pin your news - Highlight key deals, events, roles, or announcements! Neurofounders+ launches as new premium membership with exclusive articles, recurring da … ne: Neurotech between wellness and medicine part three ( CfG ) and part four: a proposal ( CFG ) Check out these papers, please: CfG has become the world’s leading think tank on neurotech’s impact on society. Women’s Brains Can Help Unleash a $1 Trillion Opportunity ( TIME ) Your brain for sale? The new frontier of neural data ( The Conversation
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
%PDF-1.6 %���� 469 0 obj >stream h��ooܸ��Q��yq^r�����n���qqѢ�q���t��k�׀���>�����q6r ��3r�Ԉ���3�d+Z)Zg����V˖�%C�ejY�m5�JY�Z�J[t��(�`��2y�u]���M B��յ�l�¹����h%+�b4z�Vzh�Z8� � F�� �[�8 ��+ps� ���g�x"�l������`� Ф�)��}~��Wj /�b��n������zy2�B���������dv���Ɵ�����7��oW�Uhy Z��-�������= u�� �h����`b������l�nr��jr4�YM�1ؽ��?~}���I�up.��܃s��!��.�Z19Z���{���s9���n��7 Ͷj}�ku9�So `%Ylg@�2p�%g�G=U0QJ�J?6�]D� a�r]R�4�����&�� 1{�X���?o~��0ۉe�r�Q�LhHgFɦE��r��AaXw�T5�v �Pf���:�w �l2��ʁO�>k� >m�u��[� ��Z�`֪ ��*W=�i�@��Aܲ �8��Z *2臞�����k��q�S�k薤\ˋn����v9$���R)QU�� �AV … 9ca8f01c1c6 xmp.did:cbc367d9-4701-429d-9026-7a907cb2ccae default converted from application/x-indesign to application/pdf Adobe InDesign 19.0 (Windows) / 2023-11-20T15:32:19+01:00 application/pdf Adobe PDF Library 17.0 False endstream endobj 438 0 obj > endobj 440 0 obj >>> endobj 456 0 obj >/Font >>>/Fields[]>> endobj 457 0 obj >stream H��Wˎ � ��W�L)�$�l� {� l�0ZcW�8"�U��t1 C���++�I��o����| ��';b�3���� =~}�����_��Xig_kEw�.X7���a��9 ���YGx �x����ӗr�������ӟ���ף������{
EUNOS European Neuro-Ophthalmology - Home | neuroClues LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy
NeuroClues.us Inc. - Neuroscience 2026 Skip to Main Content NeuroClues.us Inc. Event starts in: 00 DAYS 00 HRS 00 MINS 00 SECS November 14 to November 18, 2026 Walter E. Washington Convention Center Washington, D.C. Advertising & Sponsorship Opportunities Program & Exhibit Guide Advertising Product Theater Application Form Expo Suite My Neuroscience Marketplace Additional Sponsorship Opportunities Floor Plan Resources Prospectus & Rules and Regulations Exhibit Space Fees Dates & Deadlines Future Meetings Quick Links Exhibitor List FAQs Login NeuroClues.us Inc. Booth #834 About
"Early commercialisation with neuroClues CCO Bart Stulens on GS MedTech Podcast" | Damé Medarski posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking C
neuroClues wants to put high-speed eye-tracking tech in the doctor's office | TechCrunch –:–:–:– The first StrictlyVC of 2026 hits SF on April 30. Tickets are going fast. Register now. Founder Summit ticket savings of up to $190 end June 26. Join 1,000+ founders and VCs for all-day bootcamp. REGISTER NOW. Close TechCrunch Desktop Logo TechCrunch Mobile Logo Latest Startups Venture Apple Security AI Apps Disrupt 2026 Events Podcasts Newsletters Search Submit Site Search Toggle Mega Menu Toggle Topics Latest AI Amazon Apps Biotech & Health Climate Cloud Computing … 17;s, multiple sclerosis and stroke. The startup is in the process of filing an application for FDA approval and hoping to gain clearance for use of its device as a clinical support tool in the U.S. later this year. It is working on the same type of application in the European Union and anticipates gaining regulatory approval in the EU in 2025. So how does the device work? The patient looks through the headset and sees a screen where dots appear. A clinician will then tell th … nnouncing the close of a €5 million pre-Series A round of funding, led by White Fund and the European Commission’s EIC Accelerator program. Existing investors Invest.BW, plus a number of business angels, including Fiona du Monceau, former Chair of the Board at UCB, Artwall, and Olivier Legrain, CEO of IBA, also participated. Including this round, neuroClues has raised a total of €12 million since being founded back in 2020. Pouppez said it will be looking to raise a Ser
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
NeuroClues: the clinical must-have for Neurologists: clinical validation, industrialization, and go-to-market. | NeuroClues: the clinical must-have for Neurologist | Project | Fact Sheet | HORIZON | CORDIS | European Commission Skip to main content (opens in new window) Log in Log in English en Select your language Close CORDIS languages: es español de Deutsch en English fr français it italiano pl polski Machine translation: This is a machine translation provided by the European Commission’s eTranslation service to help you understand this page. Please read the conditions of use . български es … Results Project Information NeuroClues: the clinical must-have for Neurologist Grant agreement ID: 190152225 DOI Each project (from H2020 onwards) is attributed a Digital Object Identifier (DOI) 10.3030/190152225 EC signature date 6 April 2023 Start date 1 February 2023 End date 31 January 2027 Funded under The European Innovation Council (EIC) Total cost The total amount of money invested in the project. The total cost includes EU contribution as well as other project costs … he sum of the EU contributions of all participants in a project is equal to the grant amount. € 2 500 000,00 2 500 000,00 3 057 786,50 Investment in EU policy priorities The 'EU Policy Priority' trackers document the expenditures of the Research and Innovation framework program in specific policy areas that have established spending targets, such as climate and biodiversity. These trackers also cover areas where the Commission has reporting requirements, including clean air, … nto topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project. HORIZON-EIC-2022-ACCELERATOROPEN-01 - EIC Accelerator Open See all projects funded under this topic Funding Scheme Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation … ator Blended Finance See all projects funded under this funding scheme Call for proposal Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding. (opens in new window) HORIZON-EIC-2022-ACCELERATOR-01 See all projects funded under this call Coordinator P3 LAB Net EU contribution Net EU financial contribu
La medtech neuroClues remporte un Prix Santé Future - Carnot Institut du Cerveau | Le réseau des Carnot Aller au contenu principal Le réseau des Carnot La recherche pour l’innovation des entreprises Menu Navigation principale Le réseau Le label Carnot Notre mission La Charte Carnot Chiffres clefs Le Réseau des Carnot Le bureau L' équipe Rapports d'activité Documentation Pourquoi ce nom? 39 Carnot Pour les entreprises Recherche pour l'innovation des entreprises Des réponses R&D pour secteurs économiques Exemples de partenariats Carnot entreprises Propriété intellectuelle Rend
Eyes Are The Windows To Brain … - Science For Care - Apple Podcasts Search Home New Top Charts Search September 6, 2024 7 min Eyes Are The Windows To Brain Health Science For Care Play Imagine being able to detect neurological diseases like Parkinson's, Alzheimer's, or multiple sclerosis years before symptoms even surface. It sounds like science fiction, but it's quickly becoming a reality thanks to advances in eye-tracking technology. In this episode of Science for Care , host Anca Petre explores how tracking subtle eye movements can unlock critical insights into our brain health. Joined by e
Parkinson opsporen door oogbewegingen te meten: ‘Ons doel is een stethoscoop voor het brein’ | de Volkskrant Direct naar artikelinhoud Rubrieken Ontdek Bewaarde artikelen Krant Nieuwsbrieven Puzzels Overlijdensberichten Over ons Rubrieken AI & Tech Beter Leven Auto en fiets Koken en Eten Opvoeden Binnenland Buitenland Cartoons Columns Cultuur & Media Beeldende kunst Boeken Films Games Muziek Series Televisie Theater Economie Foto Mensen Opinie Luister Politiek Specials Sport Volkskrant Magazine Wetenschap U bent niet ingelogd. Vandaag Aardbeving Venezuela Hitte in Europa WK voetbal Ser
NeuroClues veut mieux détecter Parkinson Menu Rechercher La chaîne Accès Illimité Mon actu Journal S'identifier Ma commune Départements Charente Maritime Dordogne Gironde Landes Lot-et-Garonne Pyrénées-Atlantiques Votre région Actualité International Politique Municipales 2026 Environnement Santé Société Éco & Entreprises Faits divers Sport Tout le sport Football Rugby Raffut Golf Tennis Basket Surf Sports mécaniques Hockey Résultats Coupe du monde 2026 Loisirs Culture Diverto Gastronomie Idées Télévision Programme TV Tourisme Vin Auto-moto Bien-être Services Archives Club abonnés Jeux Hor … ons ' + ' Sud Ouest Toute l'actualité de votre région en continu sur notre application Voir La start-up promet « des biomarqueurs objectifs issus d’un examen en dix minutes des mouvements oculaires ». © Crédit photo : P3Lab Réservé aux abonnés Lecture 1 min Accueil Économie & entreprises NeuroClues veut mieux détecter Parkinson La start-up promet « des biomarqueurs objectifs issus d’un examen en dix minutes des mouvements oculaires ». © Crédit photo : P3Lab Pa
👏 Congratulations to neuroClues on raising €10M to transform the diagnosis of neurological diseases European medtech company neuroClues has announced a €10M Series A round, complemented by… | WE Venture LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in … n largely subjective. The investment round was led by Teampact.ventures , White Fund SA , and the EIC Fund, with support from existing investors including invest.bw , LeanSquare and Wallonie Entreprendre . A promising breakthrough for earlier, more accurate diagnoses and a direct impact on patient care. 💻 Read the full story on L'Echo : https://lnkd.in/eD6MgMqA With Antoine Pouppez , Pierre Daye , Pierre Pouget and Sophie Sauvage . 34 3 Comments Like Comment Share Copy Linke … neuroClues has raised €10M in Series A funding led by Teampact.ventures , White Fund SA, and the European Innovation Council Fund to scale an AI-powered eye-tracking platform for objective neurological biomarkers across Europe. What matters here is where the AI sits in care delivery. neuroClues is not positioning itself as another retrospective analytics layer. Its CE-marked Class IIa device captures high-speed infrared eye-movement data during a normal neurology visit, then … ed: €25M ● HQ: Louvain-la-Neuve, Belgium ● Investors: Teampact.ventures ; White Fund SA ; European Innovation Council Fund; invest.bw ; LeanSquare ; Wallonie Entreprendre ● Partners: Institut du Cerveau – Paris Brain Institute (2026) 77 5 Comments Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Vera Dimitrova 2mo Edited Report this post Proud to be part of a team that just made this happen. Newfund announces the final close of HEKA at €60M, the o … is happen. Newfund announces the final close of HEKA at €60M, the only European fund entirely dedicated to BrainTech. A new market is emerging at the convergence of AI, advanced imaging, digital therapeutics and biotech applied to the brain. It's growing fast, dominated 85% by the US. Yet Europe holds a major scientific edge in neuroscience. The
🧠 Great milestone for neuroClues! Pierre Daye recently visited LOU Rugby's training centre with Benjamin Kayser (Teampact.ventures) to demo our protocol to French internationals Dylan CRETIN and… | Antoine Pouppez LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices
#44 Antoine Pouppez "Ma passion a toujours été d'amener une idée vers une réalisation" - EuroQuity Podcast | Acast Suivre Partager Play EuroQuity Podcast #44 Antoine Pouppez "Ma passion a toujours été d'amener une idée vers une réalisation" Saison 4 , Ep. 44 • mardi 11 juin 2024 Découvrez l'histoire de Antoine Pouppez, cofondateur de NeuroClues. Passionné par l'innovation en santé et la bio-ingénierie, Antoine s'est lancé dans l'aventure entrepreneuriale après une carrière enrichissante chez IBA, une entreprise de pointe dans le domaine médical. Avec la mission de
neuroClues raises €10 million Series A to become the brain’s stethoscope for early diagnosis of neurological disorders | EU-Startups Sign in Magazine Interviews Re-/Launch Funding Acquisitions Other Stuff Know-How Summit Event Overview Agenda Get Tickets Job Board Job Board Post a Job Insights Startup Sourcing Premium Reports Podcast Database Startup Database Investor Database About us Mission / Team Advertising Our Newsletter – CLUB – Register Now Log In CLUB Benefits Sign in Welcome! Log into your account your username your password Forgot your password? Password recovery Recover … sed by the company to €25 million. The round is led by Teampact Ventures, White Fund and the EIC Fund (European Innovation Council), with participation from existing investors (InvestBW, Leansquare, Wallonie Entreprendre) and the support of Olivier Legrain, Chairman of the Board and CEO of IBA. “This Series A validates our technology and our ability to execute. CE certification in five months. First commercial deployments within weeks. A normative database project with … al investors. Tags Antoine Pouppez biomarkers European Innovation Council (EIC) Fund InvestBW LeanSquare medtech neuroClues neurological disorders Olivier Legrain Pierre Daye Pierre Pouget Teampact Ventures wallonie entreprendre White Fund Share Facebook Twitter WhatsApp Linkedin Previous article British GovTech scale-up Fivium secures BGF investment to scale public sector software offering Next article David Trayford, communication expert and creator of talkware, will join t
Antoine Pouppez, président et Cofondateur de neuroClues – 30/04 Menu Radio Direct Bugdet 2027 Les hôpitaux en surchauffe Entreprises International Économie et social Défense Tech Bourse Patrimoine Immobilier Emploi Conso Crypto Auto Luxe Espace pro BFM En ce moment Précédent Suivant Bugdet 2027 Les hôpitaux en surchauffe Les prix du pétrole La France face à la canicule Baisse de la productivité Gel des loyers à New York Tous les directs BFM Business Direct TV Direct Radio Tous les formats Émissions Podcasts Vidéos Newsletters Évènements Toutes les rubriques Économie et Social Toute l'actu
Le Pitch : NeuroClues développe un stéthoscope du cerveau - 28/01 Menu Radio Direct Bugdet 2027 Les hôpitaux en surchauffe Entreprises International Économie et social Défense Tech Bourse Patrimoine Immobilier Emploi Conso Crypto Auto Luxe Espace pro BFM En ce moment Précédent Suivant Bugdet 2027 Les hôpitaux en surchauffe Les prix du pétrole La France face à la canicule Baisse de la productivité Gel des loyers à New York Tous les directs BFM Business Direct TV Direct Radio Tous les formats Émissions Podcasts Vidéos Newsletters Évènements Toutes les rubriques Économie et Social Toute l'act
Apple Podcast：《EuroQuity Podcast》〈#44 Antoine Pouppez "Ma passio⋯〉 搜尋 首頁 新發現 熱門排行榜 搜尋 2024年6月11日 32 分鐘 #44 Antoine Pouppez "Ma passion a toujours été d'amener une idée vers une réalisation" EuroQuity Podcast 播放 Découvrez l'histoire de Antoine Pouppez, cofondateur de NeuroClues. Passionné par l'innovation en santé et la bio-ingénierie, Antoine s'est lancé dans l'aventure entrepreneuriale après une carrière enrichissante chez IBA, une entreprise de pointe dans le domaine médical. Avec la mission de transformer le diagnostic neurologique, NeuroClues intègre responsabilité, technologie avancée et
Eyes Are The Windows To Brain Health | neuroClues LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , an